Polio Vaccine Schedule
Children should receive four doses of inactivated polio vaccine (IPV) at ages 2 months, 4 months, 6-18 months, and 4-6 years, while most adults residing in the United States do not need routine polio vaccination unless they have specific risk factors for exposure. 1, 2
Children and Adolescents
Standard Schedule
All children require a four-dose series of IPV administered at:
- Dose 1: 2 months of age
- Dose 2: 4 months of age
- Dose 3: 6-18 months of age
- Dose 4: 4-6 years of age (before or at school entry)
Important exception: The fourth dose is not needed if the third dose is administered on or after the fourth birthday. 1
Accelerated Protection
If faster protection is needed, the minimum interval between doses is 4 weeks, though the preferred interval between the second and third doses is 2 months. 1
Catch-Up Vaccination
For incompletely vaccinated children, no additional doses are needed if more time than recommended elapses between doses. Simply complete the series to reach a total of four doses—timing delays don't require restarting the series. 1 The 2025 guidelines now explicitly include catch-up vaccination for those up to age 18 years. 3
Adults (≥18 Years)
Routine Vaccination
Routine polio vaccination of adults residing in the United States is not necessary. Most adults have minimal risk for poliovirus exposure and are already immune from childhood vaccination. 1, 2
High-Risk Adults Requiring Vaccination
Vaccination is recommended for adults at increased risk for poliovirus exposure, including:
- Travelers to areas where polio is endemic or epidemic
- Healthcare workers with close contact to patients potentially excreting polioviruses
- Laboratory workers handling specimens that may contain polioviruses
- Members of communities with disease caused by wild polioviruses
Adult Primary Series
Unvaccinated adults at increased risk should receive a three-dose primary series:
- Doses 1 and 2: 4-8 weeks apart
- Dose 3: 6-12 months after the second dose
Expedited schedules when protection is needed urgently:
- If >8 weeks available: three doses at least 4 weeks apart
- If 4-8 weeks available: two doses at least 4 weeks apart
- If <4 weeks available: single dose (complete series later if risk persists)
Booster Doses
Adults who completed a primary series and remain at increased risk can receive one additional dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose for adults. 1
Updated 2023 Guidance for Unvaccinated Adults
Following the 2022 vaccine-derived poliovirus case in New York and subsequent community transmission, ACIP now recommends that all U.S. adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated complete a primary polio vaccination series with IPV, regardless of specific risk factors. 4 This represents a significant policy shift from previous risk-based recommendations and reflects the ongoing importation risk.
Key Clinical Considerations
Immunocompromised Patients
IPV should be used (not OPV) in all patients with immunodeficiency diseases and their household members. This includes patients with HIV/AIDS, severe combined immunodeficiency, hypogammaglobulinemia, leukemia, lymphoma, or those on immunosuppressive therapy. However, immunogenicity may be reduced in these populations. 2
Pregnancy
Although no adverse effects have been documented in pregnant women or fetuses, vaccination should be avoided on theoretical grounds unless immediate protection is needed. 1
Contraindications
Do not administer IPV to persons with severe allergic (anaphylactic) reactions to a previous IPV dose or to streptomycin, polymyxin B, or neomycin (trace amounts present in the vaccine). 1
Safety Profile
IPV has an excellent safety record with no serious adverse events linked to its use since expanded implementation in the U.S. in 1996. 1